Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

BIOCRYST PHARMACEUTICALS INC

BCRX · Nasdaq · CIK 0000882796 · Healthcare · Drug Manufacturers—Specialty & Generic

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

22 Form 4 transaction lines observed in the same window
2 sales · 20 option, withholding, award, gift or other lines

Last qualifying purchase2024-05-30 · LEVIN ALAN G · $50.0K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
McKee Amy EDirector
▼○○○
Stonehouse Jon PDirector
○○○
Milne Jill C.Director
○○○
MILANO VINCENTDirector
○○○
Frank StevenDirector
○○○
Barnes Alane PChief Legal Officer
○▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-05-30 · LEVIN ALAN G.

Recent Form 4 activity

0Purchases
10Sales
50Other Form 4 lines
45SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER20 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-4.9%
3M
-13.7%
6M
-15.8%
12M
+24.9%

Volatility & liquidity

Volatility
50.3%
Beta
—
Avg daily value
USD 33.0M

Valuation

Market cap
USD 2.0B
P/E
7.8×

Fundamentals

Profit margin
30.2%
ROE
—
Industry
Drug Manufacturers—Specialty & Generic

Market data

Price data up to: 2026-10-15 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, P/E, Profit margin · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
27,494,721
Previous report
34,868,460
Avg daily volume
5,955,260
Days to cover
4.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-05-30LEVIN ALAN GPurchase (P)Common Stock7,861USD 6.36USD 49,996SEC filing ↗
2024-05-24ASELAGE STEVEPurchase (P)Common Stock2,500USD 6.40USD 16,000SEC filing ↗
2024-05-20MILANO VINCENTPurchase (P)Common Stock15,000USD 6.25USD 93,750SEC filing ↗
2024-05-20Hutson Nancy JPurchase (P)Common Stock5,000USD 6.38USD 31,900SEC filing ↗
2024-05-14Thackray Helen M.Purchase (P)Common Stock30,000USD 5.86USD 175,800SEC filing ↗
2024-05-14Doyle AnthonyPurchase (P)Common Stock36,300USD 5.57USD 202,191SEC filing ↗
2024-05-13Stonehouse Jon PPurchase (P)Common Stock30,000USD 5.55USD 166,500SEC filing ↗
2024-05-13Gayer Charles KPurchase (P)Common Stock30,000USD 5.47USD 164,100SEC filing ↗
2024-05-13Galson Steven KPurchase (P)Common Stock21,940USD 5.49USD 120,451SEC filing ↗
2024-05-13Barnes Alane PPurchase (P)Common Stock5,000USD 5.53USD 27,650SEC filing ↗
2021-11-24MILANO VINCENTPurchase (P)Common Stock7,500USD 12.19USD 91,425SEC filing ↗
2021-11-23Doyle AnthonyPurchase (P)Common Stock35,258USD 12.48USD 440,020SEC filing ↗
2020-08-11Doyle AnthonyPurchase (P)Common Stock54,000USD 4.08USD 220,320SEC filing ↗

Form 4 evidence

60 transaction lines in the latest 365-day window; 332 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Stonehouse Jon PAward / grant (A)Common Stock644USD 9.70USD 6,247SEC filing ↗
2026-08-31Milne Jill C.Award / grant (A)Common Stock1,288USD 9.70USD 12,494SEC filing ↗
2026-08-31McKee Amy EAward / grant (A)Common Stock644USD 9.70USD 6,247SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Stonehouse Jon PAward / grant (A)Common Stock644USD 9.70USD 6,247SEC filing ↗
2026-08-31Milne Jill C.Award / grant (A)Common Stock1,288USD 9.70USD 12,494SEC filing ↗
2026-08-31McKee Amy EAward / grant (A)Common Stock644USD 9.70USD 6,247SEC filing ↗
2026-08-31MILANO VINCENTAward / grant (A)Common Stock1,159USD 9.70USD 11,242SEC filing ↗
2026-08-31Frank StevenAward / grant (A)Common Stock1,288USD 9.70USD 12,494SEC filing ↗
2026-06-11Stonehouse Jon PAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11SANDERS MACHELLEAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11Milne Jill C.Award / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11McKee Amy EAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11MILANO VINCENTAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11LEVIN ALAN GAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11HEGGIE THERESAAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11Galson Steven KAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-06-11Frank StevenAward / grant (A)Common Stock15,294USD 0.00USD 0SEC filing ↗
2026-05-29Stonehouse Jon PAward / grant (A)Common Stock631USD 8.91USD 5,622SEC filing ↗
2026-05-29Milne Jill C.Award / grant (A)Common Stock1,262USD 8.91USD 11,244SEC filing ↗
2026-05-29McKee Amy EAward / grant (A)Common Stock631USD 8.91USD 5,622SEC filing ↗
2026-05-29MILANO VINCENTAward / grant (A)Common Stock1,122USD 8.91USD 9,997SEC filing ↗
2026-05-29Frank StevenAward / grant (A)Common Stock1,262USD 8.91USD 11,244SEC filing ↗
2026-05-18McKee Amy ESale (S)Common Stock11,180USD 8.97USD 100,285SEC filing ↗
2026-05-13Barnes Alane PSale (S)Common Stock62,500USD 9.54USD 596,250SEC filing ↗
2026-05-13Barnes Alane POption exercise / conversion (M)Common Stock62,500USD 5.04USD 315,000SEC filing ↗
2026-04-06Menon SandeepAward / grant (A)Common Stock205,150USD 0.00USD 0SEC filing ↗
2026-03-20HEGGIE THERESASale (S)Common Stock49,933USD 10.11USD 504,823SEC filing ↗
2026-03-20HEGGIE THERESAOption exercise / conversion (M)Common Stock49,933USD 6.30USD 314,578SEC filing ↗
2026-03-16Barnes Alane PSale (S)Common Stock150,000USD 9.15USD 1,372,500SEC filing ↗
2026-03-16Barnes Alane POption exercise / conversion (M)Common Stock150,000USD 5.51USD 826,500SEC filing ↗
2026-03-02Stonehouse Jon POption exercise / conversion (M)Common Stock305,995USD 3.22USD 985,304SEC filing ↗
2026-03-02Stonehouse Jon PD (D)Common Stock305,995USD 8.64USD 2,643,797SEC filing ↗
2026-02-27Stonehouse Jon PAward / grant (A)Common Stock421USD 8.75USD 3,684SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerBCRX
CIK0000882796
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history332 transaction lines from 2020-03-01 to 2026-08-31
13 P purchase lines · 54 S sale lines · 265 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.